Amgen: Small Cell Lung Carcinoma trials

The registry lists 18 Small Cell Lung Carcinoma studies with Amgen as lead sponsor. 3 are open to participants now and 5 have results posted.

Phase 1 8Phase 2 4Phase 3 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)RecruitingNCT07778316Phase 3
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingNCT07531095Phase 1
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)RecruitingNCT06598306Phase 1
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingNCT05740566Phase 3Results posted
• AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)CompletedNCT04885998Phase 1Results posted
• Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung CancerCompletedNCT01987232Phase 1/2Results posted
• A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic ChemotherapyCompletedNCT00883181Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT07005128Phase 3
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)Active, not recruitingNCT06898957Phase 1
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCActive, not recruitingNCT06745323Phase 2
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingNCT06211036Phase 3
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)Active, not recruitingNCT06117774Phase 3
• Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung CancerApproved for marketingNCT06064500
• A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT05060016Phase 2
• A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLCSuspendedNCT03392064Phase 1
• Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT03319940Phase 1
• A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin AlfaCompletedNCT00119613Phase 3